TM Johanns, GP Dunn - The Cancer Journal, 2017 - journals.lww.com
Glioblastoma (GBM) remains a significant cause of cancer-related mortality in pediatric and adult patients with limited treatment options. Immunotherapy represents a promising new …
Immunotherapy applications to glioblastoma represent a new treatment frontier. Antigen- targeted immunotherapy approaches hold enormous potential to elicit antigen-specific anti …
Neoantigens represent promising targets for personalized cancer vaccine strategies. However, the feasibility of this approach in lower mutational burden tumors like glioblastoma …
T Nejo, H Matsushita, T Karasaki, M Nomura… - Cancer immunology …, 2019 - AACR
Immune-based therapies have shown limited efficacy in glioma thus far. This might be at least in part due to insufficient numbers of neoantigens, thought to be targets of immune …
TM Johanns, EAR Garfinkle, KE Miller… - Clinical Cancer …, 2024 - AACR
Purpose: Outcomes for patients with glioblastoma (GBM) remain poor despite multimodality treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options …
K Woroniecka, PE Fecci - Neuro-oncology, 2020 - academic.oup.com
The ability of glioblastoma (GBM) to successfully evade and escape immunity has thwarted many of the immunotherapeutic efforts taken up against it thus far. Despite intracranial …
TA Mishchenko, VD Turubanova… - Frontiers in …, 2024 - frontiersin.org
Glioma is the most common primary brain tumor, characterized by a consistently high patient mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial …
Despite some success in secondary brain metastases, targeted or immune-based therapies have shown limited efficacy against primary brain malignancies such as glioblastoma …